LAM561

DRUG4 trials

Sponsors

Laminar Pharmaceuticals

Conditions

Glioblastoma (GBM)Glioblastoma MultiformeGliomaHigh-grade GliomaOther Solid TumoursPrimary GlioblastomaSolid Tumor, Unspecified, Child

Phase 1

A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours

CompletedNCT01792310

Laminar PharmaceuticalsGlioma, Other Solid Tumours

Start: 2013-05-31End: 2016-09-30Updated: 2023-02-21

A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients

CompletedNCT03867123

Laminar PharmaceuticalsGlioblastoma (GBM)

Start: 2018-12-04End: 2020-07-01Updated: 2023-02-21

Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors

RecruitingNCT04299191

Laminar PharmaceuticalsHigh-grade Glioma, Solid Tumor, Unspecified, Child

Start: 2020-09-01End: 2026-12-31Target: 28Updated: 2025-11-20

Phase 2

LAM561 With RT and TMZ for Adults With Glioblastoma

Active, not recruitingNCT04250922

Laminar PharmaceuticalsGlioblastoma Multiforme, Primary Glioblastoma

Start: 2019-12-01End: 2026-11-30Updated: 2025-11-20

Related Papers

Abstract 4729: Incorporation of the antitumor compound 2OHOA and its metabolite into cell membranes

Cancer Research2024-03-221 citations

A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma.

2023-07-2411 citations

Final report of a phase I study of 2-hydroxyoleic acid (2OHOA) a novel sphingomyelin synthase activator in patients (pt) with advanced solid tumors (AST) including recurrent high grade gliomas (rHGG).

Journal of Clinical Oncology2017-05-209 citations

Abstract CT067: 2-hydroxyoleic acid (2-OHOA), a novel activator of sphingomyelin synthase with antitumor activity in refractory glioblastoma: results of the first-in-human dose-escalation (DE) study in patients with advanced solid tumors (AST) and refractory gliomas/glioblastomas

Cancer Research2016-07-15

A phase I study of 2-hydroxyoleic acid (2-OHOA), a novel sphingomyelin synthase activator in patients (pt) with advanced solid tumors (AST) including refractory high grade gliomas/glioblastomas (GBM): Updated results of the expansion.

Journal of Clinical Oncology2016-05-201 citations

A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM).

Journal of Clinical Oncology2015-05-201 citations